Literature DB >> 24346688

How do I follow patients with early breast cancer after completing adjuvant therapy.

Jennifer M Matro1, Lori J Goldstein.   

Abstract

OPINION STATEMENT: With improvements in the detection and treatment of breast cancer, more women are surviving after diagnosis. Patients who complete adjuvant therapy require ongoing follow-up to manage toxicities, to detect recurrences early, and to provide ongoing physical and psychosocial support. Routine surveillance should be implemented, with attention to educating patients about symptoms of recurrence, such as weight loss, cough, and bone pain. An intensive surveillance strategy with the routine use of laboratory and radiographic studies does not improve outcomes and raises the cost of follow-up. Patients should have annual mammograms in conjunction with physical exam and history at appropriate intervals that increase the farther out patients are from treatment. Attention also should be focused on other routine health maintenance and cancer screening, such as colonoscopy, gynecologic examinations, and bone health/DEXA scans. In the early posttreatment period, medical oncologists are best equipped to follow these patients. However, as women live longer after a breast cancer diagnosis and treatment, transitioning care to a primary care physician or nurse practitioner is appropriate, provided these practitioners are educated about late treatment effects and managing side effects of treatment, which may continue as long as a decade. A multidisciplinary follow-up strategy with excellent communication between providers can ensure safe, convenient, and quality care to the growing population of breast cancer survivors. As the treatment of breast cancer evolves into personalized strategies based on the biologic characteristics of individual tumors, future studies will be needed to determine if a single surveillance strategy is sufficient or if individualized surveillance based on risk can improve outcomes and costs of long-term follow-up care.

Entities:  

Mesh:

Year:  2014        PMID: 24346688     DOI: 10.1007/s11864-013-0265-1

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  69 in total

1.  Unmet needs in information flow between breast cancer patients, their spouses, and physicians.

Authors:  E Salminen; J Vire; T Poussa; S Knifsund
Journal:  Support Care Cancer       Date:  2004-09       Impact factor: 3.603

2.  Soy food intake after diagnosis of breast cancer and survival: an in-depth analysis of combined evidence from cohort studies of US and Chinese women.

Authors:  Sarah J Nechuta; Bette J Caan; Wendy Y Chen; Wei Lu; Zhi Chen; Marilyn L Kwan; Shirley W Flatt; Ying Zheng; Wei Zheng; John P Pierce; Xiao Ou Shu
Journal:  Am J Clin Nutr       Date:  2012-05-30       Impact factor: 7.045

3.  Clinical practice guidelines for the care and treatment of breast cancer: follow-up after treatment for breast cancer (summary of the 2005 update).

Authors:  Eva Grunfeld; Sukhbinder Dhesy-Thind; Mark Levine
Journal:  CMAJ       Date:  2005-05-10       Impact factor: 8.262

4.  ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer.

Authors:  B C Pestalozzi; E Luporsi-Gely; L M Jost; J Bergh
Journal:  Ann Oncol       Date:  2005       Impact factor: 32.976

Review 5.  Cancer treatment and survivorship statistics, 2012.

Authors:  Rebecca Siegel; Carol DeSantis; Katherine Virgo; Kevin Stein; Angela Mariotto; Tenbroeck Smith; Dexter Cooper; Ted Gansler; Catherine Lerro; Stacey Fedewa; Chunchieh Lin; Corinne Leach; Rachel Spillers Cannady; Hyunsoon Cho; Steve Scoppa; Mark Hachey; Rebecca Kirch; Ahmedin Jemal; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2012-06-14       Impact factor: 508.702

6.  The possible role of female sex hormones in milk from pregnant cows in the development of breast, ovarian and corpus uteri cancers.

Authors:  Davaasambuu Ganmaa; Akio Sato
Journal:  Med Hypotheses       Date:  2005-08-24       Impact factor: 1.538

7.  Patterns of care in early-stage breast cancer survivors in the first year after cessation of active treatment.

Authors:  Jeanne S Mandelblatt; William F Lawrence; Jennifer Cullen; Annette L Stanton; Janice L Krupnick; Lorna Kwan; Patricia A Ganz
Journal:  J Clin Oncol       Date:  2006-01-01       Impact factor: 44.544

8.  MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer.

Authors:  Constance D Lehman; Constantine Gatsonis; Christiane K Kuhl; R Edward Hendrick; Etta D Pisano; Lucy Hanna; Sue Peacock; Stanley F Smazal; Daniel D Maki; Thomas B Julian; Elizabeth R DePeri; David A Bluemke; Mitchell D Schnall
Journal:  N Engl J Med       Date:  2007-03-28       Impact factor: 91.245

9.  Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.

Authors:  Sandra M Swain; Fredrick S Whaley; Michael S Ewer
Journal:  Cancer       Date:  2003-06-01       Impact factor: 6.860

10.  Estrone and 17beta-estradiol concentrations in pasteurized-homogenized milk and commercial dairy products.

Authors:  D A Pape-Zambito; R F Roberts; R S Kensinger
Journal:  J Dairy Sci       Date:  2010-06       Impact factor: 4.034

View more
  3 in total

Review 1.  The Efficiency of Diffusion Weighted MRI and MR Spectroscopy On Breast MR Imaging.

Authors:  Canan Altay; Pınar Balcı
Journal:  J Breast Health       Date:  2014-10-01

2.  Sustainable medical research by effective and comprehensive medical skills: overcoming the frontiers by predictive, preventive and personalized medicine.

Authors:  Guglielmo M Trovato
Journal:  EPMA J       Date:  2014-08-27       Impact factor: 6.543

3.  Early stage breast cancer follow-up in real-world clinical practice: the added value of cell free circulating tumor DNA.

Authors:  E La Rocca; M Silvestri; G Pruneri; S Di Cosimo; M C De Santis; E Ortolan; M Valenti; S Folli; F G de Braud; G V Bianchi; G P Scaperrotta; G Apolone; M G Daidone; V Cappelletti
Journal:  J Cancer Res Clin Oncol       Date:  2022-04-09       Impact factor: 4.322

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.